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The first HIV Exposed Uninfected (HEU) Infant and Child Workshop was held in Vancouver in July 
2015, hosted by the Child and Family Research Institute at the British Columbia Children’s Hospital 
and University of British Columbia. This event brought together 50 clinicians, epidemiologists, and 
basic scientists to review current knowledge of HEU infants, their clinical course, immunologic 
differences, and risk for neurodevelopmental and infectious morbidity. This Frontiers in Immunology 
Research Topic, “Immune mechanisms underlying the increased morbidity and mortality of HIV-
exposed uninfected (HEU) children,” is a product of the first HEU workshop synthesizing the 
evidence in the field. It was clear from the first workshop that there is a committed community of 
researchers who have identified the need to understand the mechanisms of increased morbidity and 
mortality in HEU infants and children, but evidence to intervene and mitigate these risks is lacking.
In high HIV burden countries, all infants and children, irrespective of HIV exposure, are 
vulnerable to high rates of infant and child mortality (1). In this context, the essential question 
is whether HEU children are any different than HIV-unexposed uninfected (HUU) children 
experiencing similar nutritional, environmental, and social constraints to health. To this end, 
particular research methodological principles require reinforcing in future HEU research. It was 
these methodological challenges and possible solutions that formed the theme of the second HEU 
Infant and Child Workshop attended by 75 HEU researchers and hosted by the KwaZulu-Natal 
Research Institute for Tuberculosis and HIV at the University of KwaZulu-Natal in Durban, South 
Africa. We report on the specific methodological challenges tackled during the workshop and 
steps to move forward.
ACCURATE CLASSiFiCATiOn OF HiV-EXpOSED CHiLDREn
Accurately excluding HIV infection and classifying infants as HEU is essential to ensuring 
integrity of HEU morbidity research to be certain that morbidity assigned to HEU infants is not 
in fact due to undiagnosed HIV-infection. Moreover, misclassification of HEU infants as HIV-
infected or delayed diagnosis of HIV infection have detrimental life-long implications. The infant 
HIV diagnostic dilemmas emerging in the setting of expanding maternal antiretroviral therapy 
(ART), prolonged infant postnatal prophylaxis, and decreasing vertical HIV transmission were 
2Slogrove et al. Second HEU Child Workshop Report
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 576
considered. With declining prevalence of infant HIV infection, 
standard HIV polymerase chain reaction (HIV-PCR) tests with 
unaltered sensitivity and specificity now have reduced positive 
predictive value. This makes confirmation of positive HIV-PCR 
results essential to rule out false positive tests. Prolonged infant 
postnatal antiretroviral (ARV) prophylaxis can reduce the viral 
load in an intrapartum HIV-infected infant sufficiently to result 
in a false negative HIV-PCR result at 6 weeks of age, requiring 
that diagnosis of infants as HIV-uninfected is reserved until 
all postnatal ARV prophylaxis has ceased (2). In the presence 
of maternal ART, extended persistence of maternal antibodies 
beyond 18  months of age has been observed in up to 14% of 
confirmed HEU infants requiring re-evaluation of the lower 
age limit at which a positive HIV serologic test is considered 
diagnostic of HIV (3). Additionally, there is a lack of precision in 
definitions related to HIV exposure with conflation of the terms 
HIV-exposed and HEU. Findings that have been described in 
original research as pertaining to HIV-exposed children, includ-
ing both HIV-infected and HIV-uninfected, are cited in narrative 
reviews as relating to HEU children specifically (4–6).
Moving forward: confirmation of positive HIV-PCR results 
should be the standard of care. Re-evaluation of the appropriate 
lower age limit at which a serologic HIV test can be used to diagnose 
HIV infection is needed. Timing of postnatal ARV prophylaxis and 
breastfeeding cessation needs to be taken into consideration when 
diagnosing infants as HIV-uninfected. The term HEU should be 
reserved for HIV-exposed children in whom HIV infection has been 
excluded. For interpretation of interim results while HEU infants 
are still breastfeeding and thus at risk of HIV infection, clear pres-
entation of the timing of HIV testing in relation to ongoing HIV 
exposure is advised.
UnDERSTAnDinG HEU iMMUnE SYSTEM 
ABERRATiOnS AnD THEiR ROLE  
in inFECTiOUS MORBiDiTY
A critical look was taken at the evidence for immune differences 
in HEU compared to HUU children. With little evidence for 
quantitative or functional differences in major lymphocyte 
subsets, there is fairly strong evidence for increased immune 
activation in HEU compared to HUU infants (7–9). Drivers 
of immune activation in HEU infants are yet to be elucidated 
but may include exposure to HIV viral particles observed to 
stimulate a non-specific hypergammaglobulinemia persisting 
long after waning of maternally derived IgG, or in response 
to subclinical chorioamnionitis in HIV-infected women (10). 
Much evidence of immune activation in HEU children comes 
from the pre-ART era when the maternal in utero environment 
was substantially different to the environment in the ART era 
with HIV viral load suppression and improved maternal health. 
Although immune deficits that may explain the clinical pattern 
of HEU infectious morbidity have been hypothesized, no study 
has linked HEU immunological aberrations to clinical manifes-
tations (6).
Moving forward: adequately powered prospective studies are 
needed that evaluate immunologic differences between HEU and 
HUU children in conjunction with clinical outcomes in the era of 
universal maternal ART.
UnDERSTAnDinG THE ROLE OF 
ADDiTiOnAL EXpOSURES in HEU  
CHiLD MORBiDiTY
HIV-exposed uninfected children experience exposures beyond 
HIV exposure that may play a role in mediating, modifying, or 
confounding the relationship between HIV exposure and the 
morbidity experienced. Two specific exposures considered at 
the workshop were the role of breastfeeding in reducing HEU 
morbidity and how best to measure this and how to evaluate the 
safety of in utero and postnatal ARV exposure.
Suboptimal Breastfeeding
Many longitudinal studies that consider child health outcomes 
collect detailed infant feeding information over time. The hope in 
collecting rich feeding detail is that it will be possible to accurately 
reflect the infant feeding reality and its effect on the outcome of 
interest in statistical models. Nevertheless, infant feeding status 
is often reduced to a single variable of simplified categories at a 
single time point. Discussion of how to optimally measure and 
compare feeding exposures in HIV-exposed infants raised the 
tension between measurement for routine surveillance purposes, 
which requires pragmatism and focus on a few key questions, 
versus measurement for research purposes that may require more 
nuanced detail and sophisticated analytic techniques to under-
stand the role of breastfeeding in reducing HEU infant morbidity. 
The lack of reliable information on rates of breastfeeding in HIV-
infected women, critical information in accurately estimating 
postnatal HIV transmission rates, was highlighted. Qualitative 
work was shared that showed infant feeding choices to be ongoing 
for mothers despite making an initial decision and that health-care 
providers who are highly influential in these initial choices often 
lack the skills to adequately transfer messages to HIV-infected 
mothers about the risk–benefit ratio of infant feeding choices. It 
is clear that breastfeeding is beneficial to child health irrespective 
of HIV exposure and every effort must be made to support both 
HIV-infected and HIV-uninfected mothers to successfully and 
safely breastfeed. However, recent evidence indicates that even 
breastfed HEU infants experience greater infectious morbidity 
than HUU infants (11, 12).
Moving forward: pragmatic indicators of breastfeeding are 
needed in national and global monitoring systems to accurately 
estimate the risk of postnatal HIV transmission. Interventions to 
support successful and safe breastfeeding need further investiga-
tion. Mechanisms of excess infectious morbidity in breastfed HEU 
infants, e.g., differences in breast milk quality, household pathogen 
exposure, and immune susceptibility amongst others, need to be 
understood.
In Utero and postnatal Antiretroviral 
Exposure
Access to maternal ART has made vertical HIV infection 
a preventable disease, and we must continue to strive for its 
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elimination. There is also the imperative though to ensure 
that the safest vertical transmission prevention interven-
tions available are provided. Little has been done to set up 
pharmacovigilance systems in high HIV burden countries. 
Most ARVs currently used are considered non-teratogenic; 
however, short-, medium-, and long-term effects of ARV expo-
sure beyond congenital anomalies are not well understood. 
Findings from Botswana shared at the workshop indicate that 
compared to HEU infants with in utero exposure to zidovudine 
monotherapy, HEU infants with triple ARV in utero exposure 
had significantly lower length-for-age at 24 months, even after 
adjusting for maternal disease severity (13). This is just one 
example of recent findings highlighting the urgent need for 
large scale pharmacovigilance and ARV safety surveillance 
that can accommodate the pace of expanding universal ART 
and inevitably changing regimens. The workshop heard about 
encouraging advances being made in statistical methods to 
appropriately evaluate the safety of in utero exposure to indi-
vidual ARVs in the context of changing ART regimens over 
time, multiple concurrent ARV drug exposures and confound-
ing by indication (14).
Moving forward: establishment of pharmacovigilance surveil-
lance systems and collaboration and pooling of research data is 
going to be necessary to achieve sufficient numbers of ART-exposed 
infants to confidently and continuously establish safety as vertical 
transmission prevention interventions evolve.
STUDY DESiGn STRATEGiES
Evidence of elevated HEU morbidity and mortality has largely 
come from secondary analyses of vertical transmission pre-
vention clinical trials, with few studies primarily designed to 
compare HEU and HUU infants for a specific morbidity (15). 
Despite the large size of the HEU child population in high 
burden countries (e.g., up to 30% of children in South Africa), 
recent studies have lacked power to draw definitive conclusions 
about differences between HEU and HUU children (12, 16). 
Indirect comparisons of HEU children to general child popula-
tion rates have provided useful information in the past but are 
no longer helpful to understand how HEU and HUU children 
from similar communities compare (17–19). To understand 
mechanisms of vulnerability in HEU children, adequately sized 
cohort studies primarily comparing HEU and appropriate HUU 
control children are required. For the evaluation of long-term 
ARV exposure safety though, establishing consented cohorts of 
HEU children with direct follow-up was not found to be feasible 
in the United Kingdom (20). As an alternative, routine national 
data is being used to monitor death and cancer in children 
born to HIV-infected mothers and exposed to ARVs. Efforts in 
the Western Cape Province of South Africa are leveraging the 
province-wide patient unique identifiers to establish a cohort 
of all pregnancies that can link mother–baby pairs to digitally 
available exposures including pharmacy records for ARV and 
other drugs and laboratory records for HIV diagnostics. This 
will allow for evaluation of birth outcomes in relation to ARV 
in utero exposure, hospitalizations for infectious and other events 
and future association with rare events such as malignancies. 
Harmonization of outcome measures, particularly birth out-
comes, infectious morbidity, growth, and neurodevelopment 
measures could aid HEU researchers in more rapidly resolving 
outstanding questions through better comparability of studies 
across different settings and different study designs.
Moving forward: adequately sized cohort studies are neces-
sary to determine mechanisms of HEU vulnerability in early 
childhood. Surveillance strategies using existing population-
based demographic surveillance sites and national databases 
may be a more feasible strategy though than cohort studies for 
long-term evaluation of in  utero ARV exposure safety. Both 
cohort and surveillance studies need to pay attention to poten-
tial confounding by socioeconomic circumstances and infant 
feeding differences.
COnCLUSiOn
HIV-exposed uninfected infants and children are currently 
not identified within global HIV monitoring frameworks, such 
as the UNAIDS Global AIDS Response Progress Reporting 
system. Consequently, there is little focus within countries on 
measuring outcomes in HEU children beyond prevention of 
vertical HIV infection. While the bigger picture of improving 
health and well-being for all children must be kept in mind, 
and one group should not be prioritized to the detriment of the 
other, the evidence is mounting that HEU children experience 
excess morbidity and mortality (21, 22). There is a pressing 
need for clinicians, program implementers, researchers, policy 
makers, and HIV-affected families to form an organized com-
munity of HEU child advocates that can coordinate placing 
HEU children in a more prominent position on the global HIV 
research and monitoring agenda. The workshop concluded with 
a reminder to think more broadly about vertical transmission 
prevention aims and to re-envisage Preventing Mother to 
Child Transmission rather as Promoting health of Mothers and 
Their Children Together with supporting Fathers and Families 
(PMTCT F2). We look forward to the third workshop in Paris 
in July 2017.
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